<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GABRB3 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GABRB3</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Gamma-Aminobutyric Acid Type A Receptor Beta 3 Subunit</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q12</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2567</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>137192</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000066248</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P28472</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>473 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~54 kDa</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Epilepsy, Angelman Syndrome, Autism Spectrum Disorder, Alzheimer's Disease, Sleep Disorders["@bill2017"]</td>
</tr>
<tr>
<td class="label">GABA EC50</td>
<td>1-10 muM</td>
</tr>
<tr>
<td class="label">Cl- conductance</td>
<td>10-30 pS</td>
</tr>
<tr>
<td class="label">Rise time</td>
<td>1-5 ms</td>
</tr>
<tr>
<td class="label">Decay time</td>
<td>50-500 ms</td>
</tr>
<tr>
<td class="label">Single channel open time</td>
<td>1-10 ms</td>
</tr>
<tr>
<td class="label">Modulation</td>
<td>Benzodiazepine, barbiturate, neurosteroid</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hypothalamus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Diazepam</td>
<td>Positive modulator</td>
</tr>
<tr>
<td class="label">Lorazepam</td>
<td>Positive modulator</td>
</tr>
<tr>
<td class="label">Phenobarbital</td>
<td>Positive modulator</td>
</tr>
<tr>
<td class="label">Propofol</td>
<td>Positive modulator</td>
</tr>
<tr>
<td class="label">Etomidate</td>
<td>Positive modulator</td>
</tr>
</table>
The GABRB3 gene (Gamma-Aminobutyric Acid Type A Receptor Beta 3 Subunit) encodes the beta3 subunit of the GABA-A receptor, a ligand-gated chloride channel that mediates the principal inhibitory neurotransmission in the mammalian central nervous system. The beta3 subunit is a critical component of most GABA-A receptor assemblies, contributing to receptors found throughout the brain and playing essential roles in neuronal inhibition, brain development, and network synchronization. The gene has been strongly implicated in epilepsy, Angelman syndrome, autism spectrum disorders, Alzheimer's disease, and other neurological and psychiatric conditions["@bill2017"] [1].
GABA-A receptors are the primary mediators of fast inhibitory neurotransmission in the brain, accounting for the vast majority of synaptic inhibition. These pentameric ligand-gated ion channels respond to gamma-aminobutyric acid (GABA) by opening a chloride channel, hyperpolarizing neurons and reducing action potential firing. The beta3 subunit is one of the most widely expressed GABA-A receptor subunits, found in approximately 30% of all GABA-A receptors in the adult brain. Its widespread distribution and ability to co-assemble with multiple alpha and gamma subunits make it essential for normal brain function [2].
The GABRB3 protein is a member of the Cys-loop family of ligand-gated ion channels, which share a common structural architecture[@macdonald2010] [3]:
N-terminal extracellular domain: Contains the signature Cys-loop motif (13 amino acids with a disulfide bond) critical for receptor assembly and function. This domain also harbors the GABA binding site at the interface with alpha subunits.
Transmembrane domains (M1-M4): Four alpha-helical transmembrane segments form the ion channel pore. The M2 segment lines the channel and determines chloride ion selectivity and conductance.
Intracellular loop: The intracellular loop between M3 and M4 is the largest domain (~150 amino acids), containing multiple phosphorylation sites and trafficking signals.
C-terminal extracellular domain: Contributes to the extracellular ligand-binding domain and subunit assembly.
The beta3 subunit has several distinctive features:
Beta3-containing GABA-A receptors are the most common subtype in the brain[@rudolph2010] [4]:
Common configurations:
Beta3-containing receptors have characteristic properties [5]:
GABRB3 shows widespread expression throughout the brain [6]:
GABRB3 expression is highly regulated during development:
Beta3-containing receptors mediate fast synaptic inhibition [7]:
Phasic inhibition: Rapid synaptic currents that terminate within milliseconds, preventing excessive neuronal firing and maintaining temporal precision in neural circuits.
Temporal processing: The fast kinetics of beta3-containing receptors enable precise timing required for sensory processing, motor coordination, and cognitive function.
Network synchronization: Beta3 receptors contribute to gamma oscillations and other network rhythms essential for information processing.
Beta3-containing extrasynaptic receptors mediate tonic inhibition [8]:
Ambient GABA: Respond to low concentrations of ambient GABA
Extrasynaptic localization: Located outside synaptic contacts
Sustained currents: Generate maintained inhibitory currents
Gain modulation: Adjust neuronal gain and excitation-inhibition balance
GABRB3 plays critical roles in development [9]:
Neuronal migration: Receptor signaling affects neuronal migration
Synaptogenesis: Beta3-containing receptors are essential for synapse formation
Circuit refinement: Activity-dependent refinement of connections
Myelination: Some evidence for roles in oligodendrocyte function
Beta3-containing receptors in the hypothalamus [10]:
Stress response: Modulate HPA axis activity
Sleep-wake regulation: Hypothalamic GABRB3 affects sleep
Energy homeostasis: Some roles in metabolic regulation
GABRB3 is strongly associated with epilepsy [1]:
Genetic epilepsy: Over 60 pathogenic variants identified in patients with genetic epilepsy syndromes, including:
Therapeutic implications: GABAergic agents are first-line treatments for many seizure types.
GABRB3 is located in the Angelman syndrome critical region on chromosome 15q11-q13 [11]:
Maternal imprinting: The region is maternally imprinted, so only the maternal allele is expressed.
Expression changes: Reduced GABRB3 expression contributes to the Angelman phenotype.
Seizures: GABRB3 dysfunction contributes to the high seizure prevalence in Angelman syndrome.
Therapeutic targeting: GABAergic agents may help normalize inhibition.
GABRB3 is strongly implicated in ASD [12]:
Genetic associations: Rare variants in ASD patients; copy number variations affecting GABRB3.
Expression changes: Altered GABRB3 expression in postmortem ASD brain tissue.
Network dysfunction: Altered inhibition may affect neural connectivity.
Comorbidity: High rates of epilepsy in ASD may involve GABRB3.
GABRB3 has implications for AD [13]:
Expression changes: Altered expression in AD brains.
Network hyperexcitability: Reduced inhibition may contribute to seizures in AD.
Cognitive dysfunction: Altered GABAergic signaling affects memory circuits.
Therapeutic potential: GABAergic agents may help normalize inhibition.
GABRB3 is relevant to sleep [14]:
Sleep architecture: Beta3-containing receptors regulate sleep-wake cycles.
Sedative medications: Many sleep medications act on beta3-containing receptors.
Circadian regulation: Some roles in circadian sleep regulation.
GABRB3 may contribute to anxiety [15]:
Genetic associations: Some genetic variants associated with anxiety.
Anxiolytic drugs: Benzodiazepines act on beta3-containing receptors.
Circuit modulation: Beta3 receptors in anxiety circuits.
GABRB3 may be relevant to other psychiatric disorders:
Depression: Some associations with major depressive disorder.
Schizophrenia: Altered GABAergic signaling in schizophrenia includes GABRB3.
Bipolar disorder: Some genetic associations reported.
Beta3-containing GABA-A receptors mediate inhibition through a well-characterized mechanism [16]:
GABRB3 expression is tightly regulated:
Transcriptional regulation: Activity-dependent and developmental regulation
Post-translational regulation:
Beta3 subunits interact with:
Subunit-selective compounds: Developing alpha/beta3-selective compounds.
Extrasynaptic targeting: Targeting delta-containing receptors.
Allosteric modulators: Developing novel allosteric sites.
GABRB3 knockout mice show [17]:
Transgenic and conditional knockout models are used to study cell-type-specific functions.
The study of GABRB3 has provided critical insights into GABAergic inhibition and its role in neurological disease. The beta3 subunit is one of the most widely expressed GABA-A receptor subunits, making it essential for normal brain function.
Early research characterized the pharmacological properties of GABA-A receptors, identifying the beta3 subunit as a key component of receptor assemblies throughout the brain. The development of subunit-selective compounds enabled detailed functional studies.
The identification of GABRB3 mutations in patients with epilepsy, Angelman syndrome, and autism established its clinical importance. Mouse models lacking GABRB3 demonstrated the critical role of this subunit in brain development and function.
More recent investigations have explored GABRB3 as a therapeutic target. The development of subtype-selective compounds offers hope for more targeted treatments with fewer side effects.
The following diagram shows the key molecular relationships involving GABRB3 Gene discovered through SciDEX knowledge graph analysis: